Skip to main content

Erratum to: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol

Erratum

In the original publication [1] the last sentence under the paragraph “Adverse event management” not correct. The correct version can be found here:

“SAEs that occur between trial entry and up to 28 days after completion of the study drug will be reported”.

Reference

  1. 1.

    McAuley DF. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol. Trials. 2013;14:10.1186/1745-6215-14-51.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Daniel F. McAuley.

Additional information

The online version of the original article can be found under doi:10.1186/1745-6215-14-51.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cross, L.J.M., O’Kane, C.M., McDowell, C. et al. Erratum to: Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction – a randomised placebo-controlled trial (KARE): study protocol. Trials 18, 214 (2017). https://0-doi-org.brum.beds.ac.uk/10.1186/s13063-017-1930-7

Download citation